Podcast Pearls
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

Download this PDF summary transcript of experts’ answers to questions posed during a live symposium on hemophilia A management.
Miguel A. Escobar, MD
Mark Reding, MD
Guy A. Young, MD
Format: Adobe Acrobat (.pdf)
File Size: 211 KB
Released: January 18, 2022


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Sanofi Genzyme
Takeda Pharmaceuticals U.S.A., Inc.: Takeda Oncology Company

Information on this Educational Activity


Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received funds for research support from CSL Behring, Genentech, Novo Nordisk, Sanofi, Takeda, and UniQure (paid to institution) and consulting fees from CSL Behring, BioMarin, Genentech/Roche, HEMA Biologics , Kedrion, NHF, Novo Nordisk, Pfizer, Sanofi, and Takeda.
Mark Reding, MD

Professor of Medicine
Division of Hematology, Oncology and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Mark Reding, MD, has disclosed that he has received consulting fees from Bayer, CSL Behring, Novo Nordisk, Sanofi Genzyme, and Takeda; funds for research support from Bayer and Biomarin; and fees for non-CME/CE services from Bayer, CSL Behring, Sanofi Genzyme, and Takeda.
Guy A. Young, MD

Professor of Pediatrics
Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received funds for research support from Genentech/Roche; fees for non-CME/CE services from Bioverativ, Genentech/Roche, and Sanofi; and consulting fees from CSL-Behring, Genentech/Roche, Grifols, Hema Biologics, Kedrion, Novo Nordisk, Sanofi, Spark, and Takeda.

Program Medium

This program has been made available online.

Related Content

Enter characteristics of your patient with immune thrombocytopenia (ITP) into this online tool to see recommendations from 5 experts

Hanny Al-Samkari, MD Catherine M. Broome, MD Sandhya Ramanathan Panch, MD, MPH person default Kristin Ammon Shimano, MD Released: October 26, 2022

Dr Hanny Al-Samkari of Harvard Medical School and Massachusetts General Hospital reviews current and investigational treatments for ITP, from Clinical Care Options (CCO)

Hanny Al-Samkari, MD Released: October 18, 2022

Experts present emerging strategies for treatment of hemophilia A and B with the goal of restoring hemostatic balance, from Clinical Care Options (CCO)

Guy A. Young, MD
Program Director
Glaivy Batsuli, MD Allison Wheeler, MD, MSCI
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 26, 2022 Expired: September 25, 2023

On-demand webcast of a live symposium at THSNA 2022 with experts discussing the management of immune thrombocytopenia, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil
Program Director
Catherine M. Broome, MD Cindy Neunert, MD, MSCS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 15, 2022 Expired: September 14, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings